Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EC Healthcare

醫思健康

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2138)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The board (the "Board") of directors (the "Directors" and each a "Director") of EC Healthcare (the "Company", together with its subsidiaries, the "Group") hereby announces that on 1 August 2022, the Company granted the options (the "Share Options") to 3 employees, namely Employee A, Employee B and Employee C (each a "Grantee" and collectively the "Grantees"), subject to acceptance by the Grantees, under the share option scheme adopted by the Company on 19 February 2016 (the "Share Option Scheme"). Details of Share Options granted are as follows:

Date of Grant: 1 August 2022

Exercise price of Share Options granted:

HK\$8.04 per share of the Company (the "Share") for the aggregate of 2,200,000 Share Options granted to Employee A, HK\$9.15 per Share for the aggregate of 300,000 Share Options granted to Employee B and HK\$9.15 per Share for the aggregate of 1,000,000 Share Options granted to Employee C, which are:

- (i) higher than the closing price of HK\$6.87 per Share as stated in the daily quotation sheets issued by the Stock Exchange on the date of grant of the Share Options, i.e. 1 August 2022;
- (ii) higher than the average closing price of HK\$7.036 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the date of grant of the Share Options; and
- (iii) higher than the nominal value of HK\$0.00001 per

Share.

Number of Share Options granted:

An aggregate of 3,500,000 Share Options to the Grantees (each Share Option shall entitle the holder thereof to subscribe for one (1) Share), comprising 2,200,000 Share Options to Employee A, 300,000 Share Options to Employee B and 1,000,000 Share Options to the Employee C.

Validity period of the Share Option:

The details of the vesting schedule for each of the Grantees are as follows:

Vesting schedule of Employee A:

- (i) 440,000 (20%) of the Share Options shall vest on the Employee A on 31 July 2023, and shall be exercisable until 31 July 2032 (both dates inclusive);
- (ii) 440,000 (20%) of the Share Options shall vest on the Employee A on 31 July 2024, and shall be exercisable until 31 July 2032 (both dates inclusive);
- (iii) 440,000 (20%) of the Share Options shall vest on the Employee A on 31 July 2025, and shall be exercisable until 31 July 2032 (both dates inclusive);
- (iv) 440,000 (20%) of the Share Options shall vest on the Employee A on 31 July 2026, and shall be exercisable until 31 July 2032 (both dates inclusive); and
- (v) 440,000 (20%) of the Share Options shall vest on the Employee A on 31 July 2027, and shall be exercisable until 31 July 2032 (both dates inclusive).

Vesting schedule of Employee B:

- (i) 100,000 Share Options shall vest on Employee B on 31 July 2023, and shall be exercisable until 31 July 2032 (both dates inclusive);
- (ii) 100,000 Share Options shall vest on Employee B on 31 July 2024, and shall be exercisable until 31 July 2032 (both dates inclusive); and
- (iii) 100,000 Share Options shall vest on Employee B on 31 July 2025, and shall be exercisable until 31

July 2032 (both dates inclusive).

<u>Vesting schedule of Employee C:</u>

- (i) 200,000 (20%) of the Share Options shall vest on the Employee C on 31 July 2023, and shall be exercisable until 31 July 2032 (both dates inclusive);
- (ii) 200,000 (20%) of the Share Options shall vest on the Employee C on 31 July 2024, and shall be exercisable until 31 July 2032 (both dates inclusive);
- (iii) 200,000 (20%) of the Share Options shall vest on the Employee C on 31 July 2025, and shall be exercisable until 31 July 2032 (both dates inclusive);
- (iv) 200,000 (20%) of the Share Options shall vest on the Employee C on 31 July 2026, and shall be exercisable until 31 July 2032 (both dates inclusive); and
- (v) 200,000 (20%) of the Share Options shall vest on the Employee C on 31 July 2027, and shall be exercisable until 31 July 2032 (both dates inclusive).

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, each of the Grantees is neither a Director, chief executive nor substantial shareholder of the Company nor an associate (as defined under the Listing Rules) of any of them.

By order of the Board EC Healthcare Raymond Siu Company Secretary

Hong Kong, 1 August 2022

As at the date of this announcement, the executive Directors are Mr. Tang Chi Fai, Mr. Lu Lyn Wade Leslie, Mr. Lee Heung Wing, Ms. Wong Ka Ki Ada and Mr. Wong Chi Cheung, the non-executive Director is Mr. Luk Kun Shing Ben, and the independent non-executive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Lam Chi Hang Josekin.